Wilms' tumor 1-derived peptide-MHC complex (WT1-pMHC) (WT1-pMHC)

Wilms' tumor 1 (WT1) is a zinc-finger transcription factor that plays a critical role in urogenital development and is highly overexpressed in various hematological malignancies and solid tumors, while maintaining restricted expression in normal adult tissues (UniProt P19544). WT1-derived peptide epitopes are short amino acid sequences resulting from the intracellular proteasomal degradation of the WT1 protein, which are subsequently loaded onto Major Histocompatibility Complex (MHC) Class I and Class II molecules for presentation on the cell surface (PubMed: 15150595). These WT1-pMHC complexes serve as specific targets for the immune system, allowing CD8+ cytotoxic T cells and CD4+ helper T cells to recognize and eliminate malignant cells. Therapeutic strategies targeting these epitopes include peptide-based vaccines, such as Galinpepimut-S, designed to stimulate endogenous immune responses, and adoptive cell therapies like T-cell receptor (TCR) engineered T cells (PubMed: 28811011). Because WT1 was ranked as the top priority antigen for cancer immunotherapy by the National Cancer Institute, these epitopes are central to developing precision oncology treatments for diseases like acute myeloid leukemia and mesothelioma (PubMed: 19723647). The clinical success of these therapies often depends on the patient's specific HLA genotype, as different MHC molecules present different WT1-derived peptides.

Other names

WT1 peptide-HLA complexWilms tumor 1 epitopesWT1-derived MHC ligandsWT1-pMHC

Induction of cytotoxic T-lymphocyte (CTL) response and helper T-cell response through recognition of peptide-MHC complexes by T-cell receptors (TCRs).